Trinity Biotech

Trinity Biotech is a medical diagnostic company that develops, manufactures, and markets products for clinical laboratories and point-of-care settings. Founded in 1992 and headquartered in Bray, Ireland, the company offers a diverse portfolio of over 400 products aimed at detecting various health conditions, including infectious diseases, autoimmune disorders, sexually transmitted infections, and diabetes. Its product range includes diagnostic tests and instrumentation for conditions such as Lyme disease, syphilis, herpes, and diabetes monitoring through haemoglobin A1c testing. Additionally, Trinity Biotech provides products in immunofluorescence assays and enzyme-linked immunosorbent assays, along with raw materials for the life sciences sector. The company's sales strategy involves a direct sales force, independent distributors, and strategic partners, targeting public health facilities, hospitals, clinical laboratories, and research institutions. With a focus on both organic growth and acquisitions, Trinity Biotech is positioning itself as a significant player in the global diagnostics industry.

Des Fitzgerald

Director Corporate Development

John Gillard

CEO

6 past transactions

Immco Diagnostics

Acquisition in 2013
Immco Diagnostics incorporates innovative medical devices, diagnostic laboratory testing expertise and pioneering research for a comprehensive solution to autoimmune disease diagnostics.

Fiomi Diagnostics

Acquisition in 2012
Fiomi Diagnostics is develops a panel of point-of-care cardiac marker assays. The company’s forecast technology enables picomolar sensitivity for whole-blood in vitro diagnostic immunoassays at the point of care. Its technology is based on a microstructured plastic chip, which provides a highly repeatable flow of fluid in lateral flow assays and an efficient fluorescence detection system providing quantitative test results.

Phoenix Biotech

Acquisition in 2011
Phoenix Biotech specializes in developing and manufacturing medical diagnostic products and technical services tailored for the automation of diagnostic systems. The company offers a range of recombinant-based enzyme-linked immunosorbent assay (ELISA) products focused on infectious diseases, including the TREP-SURE EIA, which detects treponema pallidum antibodies in human serum and plasma, and the TREP-CHEK Test Kit, designed for the confirmatory qualitative detection of treponema pallidum IgG antibodies. Additionally, Phoenix Biotech produces a syphilis total antibody test that detects both IgG and IgM antibodies, further enhancing its portfolio of diagnostic solutions.

Primus Corp

Acquisition in 2005
Primus Corp is designs, manufactures, and supplies hemoglobin variant testing, thalassemias, and newborn screening systems. It offers direct injection and automated analyzers; and dual-assay analyzers for the measurement of HbA1c, as well as in the identification and quantization of A2, F, and Hb variants. The company provides PDQ, a semi-automated equipment for the physician's office, clinics, and medium-size hospital laboratories; PDQ Plus, an automated equipment and method for clinics, medium-size and large hospitals, and reference labs; and Primus ultra2 resolution, a system for the detection of hemoglobinopathies using whole blood, manual hemolysates, or blood spot samples on filter paper.
Fitzgerald Industries International is a manufacturer and supplier of biological reagents based in Acton, Massachusetts. The company specializes in primary and secondary antibodies, recombinant and native proteins, ELISA kits, as well as serum and plasma products. Fitzgerald is committed to addressing the specific needs of researchers by providing personalized technical support alongside its high-quality products. The company's approach emphasizes exceptional customer service and competitive pricing, with a core team of scientists who understand the challenges faced in laboratory environments. This combination of expertise and dedication aims to foster strong relationships with customers while supporting their scientific endeavors.

MarDx Diagnostics

Acquisition in 2000
MarDx Diagnostics is engages in developing, manufacturing, and marketing diagnostic products in the United States. It offers Western Blot, which is used to test and confirm the primary diagnosis of certain infectious diseases, including lyme disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.